The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

What Was Tested

The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks.

Lipoprotein particle profile by nuclear magnetic resonance was assessed at baseline and 26 weeks.

The lipoprotein insulin resistance (LPIR) score was calculated.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors and Insulin Resistance.

Author keywords: incretin therapy, type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in people with insulin resistance, prediabetes & type 2 diabetes.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, Insulin resistance, prediabetes & type 2 diabetes research.